Evidence map›Paper›PMID 41794022›Full record

ArticleCell reports methods2026

Rapid expansion of primary human vocal fold epithelial cells via targeted pathway inhibition and anchorage-independent sphere culture.

Xudong Shi, Ryo Suzuki, Haiyan Lu, Hua Zhang, Lingjun Li, Nathan V Welham

Abstract read
In one paragraph

Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xudong ShiDepartment of Otolaryngology - Head and Neck Surgery, University of Wisconsin-Madison, Madison, WI 53792, USA.
Ryo SuzukiDepartment of Otolaryngology - Head and Neck Surgery, University of Wisconsin-Madison, Madison, WI 53792, USA.
Haiyan LuDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.
Hua ZhangDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.
Lingjun LiDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA; Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA.
Nathan V WelhamDepartment of Otolaryngology - Head and Neck Surgery, University of Wisconsin-Madison, Madison, WI 53792, USA. Electronic address: nvwelham@wisc.edu.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
PHONOSURGICAL OPTIMIZATION CRITERIA FOR SULCUS VOCALISR01DC004428 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI Nathan Welham · 2000 to 2026
$8.7M
Mass Spectrometric Studies of Neuropeptides in FeedingR01DK071801 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2006 to 2026
$6.7M
Regeneration of Multi-Layered Vocal Fold MucosaR01DC010777 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI WELHAM, NATHAN · 2010 to 2020
$5.3M
Creating a region- specific biomolecular atlas of the brain of Alzheimer’s diseaseR01AG078794 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI, Luigi Puglielli · 2022 to 2026
$3.7M
Pathophysiological profiling of vocal fold hyperkeratosisR01DC019357 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI SHERRY A TANUMIHARDJO, Nathan Welham · 2022 to 2026
$2.7M
DiLeu-enabled multiplexed quantitation for biomarker discovery and validation in Alzheimer’s diseaseR01AG052324 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2023 to 2026
$2.3M
Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical ResearchS10RR029531 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
$2.1M
Acquisition of a Dual-Source, High-Performance, Ion Mobility, Quadrupole Time-of-Flight Mass Spectrometry System for Biomedical Research at UW-MadisonS10OD028473 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2021 to 2021
$1.3M
Acquisition of a High Resolution High Speed MALDI Mass Spectrometer for Biomedical Research at UW-MadisonS10OD025084 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2018 to 2018
$598k
Anchorage-independent culture for maintaining vocal fold epithelial stem cellsR21DC017836 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI SHI, XUDONG, WELHAM, NATHAN · 2019 to 2020
$421k
NCI NIH HHS P30 CA014520NCRR NIH HHS S10 RR029531NIA NIH HHS R01 AG052324NIA NIH HHS R01 AG078794NIDCD NIH HHS R01 DC004428NIDCD NIH HHS R01 DC010777NIDCD NIH HHS R01 DC019357NIDCD NIH HHS R21 DC017836NIDDK NIH HHS R01 DK071801NIH HHS S10 OD025084NIH HHS S10 OD028473
6 · The paper itself

Abstract

Vocal fold epithelial cells (VFEs) serve critical physiologic and immunologic functions at the boundary between the upper and lower airways but are difficult to maintain and expand in primary cultures. This technical challenge has impeded progress in VFE biology as well as cell banking for translational applications. Here, using primary human VFEs, we show that simultaneous inhibition of transforming growth factor β (TGF-β), Rho-associated protein kinase (ROCK), and Notch signaling with a small-molecule inhibitor cocktail enables rapid proliferation, successful passaging, and long-term expansion while preserving the core epithelial phenotype. Under anchorage-independent culture conditions, VFE progenitors generate clonal spheres that can be expanded over multiple generations; sphere-dissociated VFEs then revert toward their original phenotype, which includes the ability to form stratified squamous epithelium in organotypic cocultures. Both pathway-inhibited and sphere-cultured VFEs exhibit mechanistically appropriate remodeling of the cellular proteome. These advances offer a robust toolkit for upper airway mucosal biology and regenerative medicine.

Indexed as

Cell Culture TechniquesEpithelial CellsSignal TransductionSpheroids, CellularVocal CordsCell ProliferationCells, CulturedHumansPyridinesReceptors, Notchrho-Associated KinasesTransforming Growth Factor betaPyridinesReceptors, Notchrho-Associated KinasesTransforming Growth Factor betaA-83-01cellular spheroidsCP: cell biologyCP: stem cellDAPTin vitro techniqueslarynxNotch inhibitionrespiratory mucosaROCK inhibitionTGF-β inhibitionY-27632

Identifiers

PMID41794022
PMCPMC13030965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.